Table 3.

Top modified diseases and functions from ingenuity pathway analysis.

Group comparison	Modified disease and functions	Number of genes involved	Range of p-value for genes involved
HCA–Normoxia versus No HCA–Normoxia (control)	Cancer	1,109	1.52E−118–4.15E−06
	Organismal injury and abnormalities	1,117	1.52E−118–4.74E−06
	Gastrointestinal disease	1,057	1.24E−83–3.85E−06
	Endocrine system disorders	1,004	1.95E−70–2.02E−06
	Dermatological diseases and conditions	860	5.03E−54–3.45E−06
	Neurological disease	901	2.88E−41–3.97E−06
	Reproductive system disease	809	1.65E−38–3.85E−06
	Hepatic system disease	659	1.89E−32–3.56E−06
	Cellular function and maintenance	697	2.85E−30–3.92E−06
	Protein synthesis	582	1.87E−28–3.63E−06
No HCA–Nyperoxia versus No HCA–Normoxia (control)	Cancer	482	1.26E−48–7.55E−03
	Organismal injury and abnormalities	486	1.26E−48–7.98E−03
	Endocrine system disorders	429	2.4E−32–5.49E−03
	Gastrointestinal disease	448	4.48E−32–7.47E−03
	Dermatological diseases and conditions	352	6.8E−16–7.86E−03
	Reproductive system disease	354	7.8E−16–6.34E−03
	Neurological disease	378	1.95E−15–7.86E−03
	Hepatic system disease	284	3.36E−15–6.25E−03
	Renal and urological disease	238	1.27E−09–7.98E−03
	Hereditary disorder	174	1.55E−08–7.05E−03
HCA–Hyperoxia versus No HCA–Normoxia (control)	Organismal injury and abnormalities	1,513	1.03E−43–2.43E−03
	Cell death and survival	494	5.52E−14–2.43E−03
	Infectious diseases	358	3.34E−13–2.34E−03
	Cellular development	460	3.92E−13–2.34E−03
	Cellular growth and proliferation	459	3.92E−13–2.25E−03
	Immunological disease	656	4.26E−13–2.34E−03
	Inflammatory disease	335	4.26E−13–2.34E−03
	Cellular function and maintenance	478	1.28E−11–2.36E−03
	Inflammatory response	329	1.28E−11–2.34E−03
	Cell-to-cell signaling and interaction	270	2.86E−11–2.18E−03